Effect of mu agonists on long-term survival and recurrence in nonsmall cell lung cancer patients

Medicine (United States)

Volumn 94, Issue 33, 2015, Pages e1333-

  Wang, Kai ^a   Qu, Xiao ^a   Wang, Ying ^a   Shen, Hongchang ^a   Liu, Qi ^a   Du, Jiajun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BILOBECTOMY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG USE; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; INVESTIGATIVE PROCEDURES; LONG TERM SURVIVAL; LUNG RESECTION; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; AGONISTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PAIN, POSTOPERATIVE; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; TIME; TUMOR RECURRENCE;

ANALGESICS, OPIOID; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAIN, POSTOPERATIVE; PNEUMONECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, OPIOID, MU; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; TIME;

EID: 84943157543     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001333     Document Type: Article

References (45)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108
2. International Agency for Research on C. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. World Health Organization. 2013: 1-3
3. Teh E, Belcher E. Lung cancer: diagnosis, staging, and treatment. Surgery (Oxford). 2014; 32: 242-248
4. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 1992; 101: 1013-1018
5. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241
6. Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol. 2014; 32: 1655-1661
7. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-Analysis of effectiveness and side effects. CMAJ. 2006; 174: 1589-1594
8. Lee SK, Dawson J, Lee JA, et al. Management of cancer pain: 1. Wider implications of orthodox analgesics. Int J Gen Med. 2014; 7: 49-58
9. Al-Hashimi M, Scott SW, Thompson JP, et al. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013; 111: 80-88
10. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009; 25: 170-175
11. Sessler DI, Ben-Eliyahu S, Mascha EJ, et al. Can regional analgesia reduce the risk of recurrence after breast cancer?. Methodology of a multicenter randomized trial. Contemp Clin Trials. 2008; 29: 517-526
12. Forget P, Tombal B, Scholtes JL, et al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer?. Eur J Anaesthesiol. 2011; 28: 830-835
13. Merquiol F, Montelimard AS, Nourissat A, et al. Cervical epidural anesthesia is associated with increased cancer-free survival in laryngeal and hypopharyngeal cancer surgery: a retrospective propensity-matched analysis. Reg Anesth Pain Med. 2013; 38: 398-402
14. Lin L, Liu C, Tan H, et al. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011; 106: 814-822
15. Day A, Smith R, Jourdan I, et al. Retrospective analysis of the effect of postoperative analgesia on survival in patients after laparoscopic resection of colorectal cancer. Br J Anaesth. 2012; 109: 185-190
16. Binczak M, Tournay E, Billard V, et al. Major abdominal surgery for cancer: does epidural analgesia have a long-term effect on recurrencefree and overall survival?. Ann Fr Anesth Reanim. 2013; 32: e81-e88
17. Maher DP, Wong W, White PF, et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014; 113(Suppl 1): i88-i94
18. Cata JP, Gottumukkala V, Thakar D, et al. Effects of postoperative epidural analgesia on recurrence-free and overall survival in patients with nonsmall cell lung cancer. J Clin Anesth. 2014; 26: 3-17
19. Gupta A, Bjornsson A, Fredriksson M, et al. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br J Anaesth. 2011; 107: 164-170
20. De Oliveira GS Jr, Ahmad S, Schink JC, et al. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. Reg Anesth Pain Med. 2011; 36: 271-277
21. Myles PS, Peyton P, Silbert B, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011; 342: d1491
22. Bimonte S, Barbieri A, Palma G, et al. The role of morphine in animal models of human cancer: does morphine promote or inhibit the tumor growth?. BioMed Res Int. 2013; 2013: 258141
23. Grass JA. Patient-controlled analgesia. Anesthesia Analgesia. 2005; 101(5 Suppl): S44-S61
24. Commiskey S, Fan LW, Ho IK, et al. Butorphanol: effects of a prototypical agonist-Antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005; 98: 109-116
25. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst. 1980; 65: 801-809
26. Fujisawa T, Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Cancer. 1997; 79: 474-481
27. Mountain CF, McMurtrey MJ, Frazier OH. Regional extension of lung cancer. Int J Radiat Oncol Biol Phys. 1980; 6: 1013-1020
28. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29: 1556-1563
29. Ge MJ, Shi D, Wu QC, et al. Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol. 2006; 132: 248-256
30. Sawabata N, Okumura M, Utsumi T, et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg. 2007; 55: 189-192
31. Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics. 2013; 3: 377-394
32. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg. 1995; 222: 415-423
33. Gach K, Wyrebska A, Fichna J, et al. The role of morphine in regulation of cancer cell growth. Nauny Schmiedebergs Arch Pharmacol. 2011; 384: 221-230
34. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9: e91577
35. Leo S, Nuydens R, Meert TF. Opioid-induced proliferation of vascular endothelial cells. J Pain Res. 2009; 2: 59-66
36. Singleton PA, Moreno-Vinasco L, Sammani S, et al. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007; 37: 222-231
37. Wen H, Lu Y, Yao H, et al. Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability. PLoS One. 2011; 6: e21707
38. Walters CL, Cleck JN, Kuo YC, et al. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron. 2005; 46: 933-943
39. Talka R, Salminen O, Whiteaker P, et al. Nicotine-morphine interactions at alpha4beta2, alpha7 and alpha3() nicotinic acetylcholine receptors. Eur J Pharmacol. 2013; 701: 57-64
40. Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011; 112: 558-567
41. Singleton PA, Mirzapoiazova T, Hasina R, et al. Increased muopioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014; 113(Suppl 1): i103-i108
42. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013; 119: 4103-4110
43. Androulakis N, Agelaki S, Perraki M, et al. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer. 2012; 106: 1917-1925
44. Zylla D, Kuskowski MA, Gupta K, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014[Epub ahead of print].
45. Kaye AD, Patel N, Bueno FR, et al. Effect of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. Ochsner J. 2014; 14: 216-228